

Iris A L Silva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6253663/publications.pdf>

Version: 2024-02-01

30
papers

409
citations

858243

12
h-index

889612

19
g-index

30
all docs

30
docs citations

30
times ranked

472
citing authors

#	ARTICLE	IF	CITATIONS
1	Systems Approaches to Unravel Molecular Function: High-content siRNA Screen Identifies TMEM16A Traffic Regulators as Potential Drug Targets for Cystic Fibrosis. <i>Journal of Molecular Biology</i> , 2022, 434, 167436.	2.0	3
2	Rescue of Mutant CFTR Trafficking Defect by the Investigational Compound MCG1516A. <i>Cells</i> , 2022, 11, 136.	1.8	11
3	Rare Trafficking CFTR Mutations Involve Distinct Cellular Retention Machineries and Require Different Rescuing Strategies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 24.	1.8	15
4	New drugs in cystic fibrosis: what has changed in the last decade?. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210981.	1.1	0
5	Personalized Medicine Based on Nasal Epithelial Cells: Comparative Studies with Rectal Biopsies and Intestinal Organoids. <i>Journal of Personalized Medicine</i> , 2021, 11, 421.	1.1	19
6	Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 693-723.	1.5	24
7	Pediatric population with cystic fibrosis in the centre of Portugal: Candidates for new therapies. <i>Jornal De Pediatria</i> , 2021, , .	0.9	0
8	An open-source high-content analysis workflow for CFTR function measurements using the forskolin-induced swelling assay. <i>Bioinformatics</i> , 2021, 36, 5686-5694.	1.8	6
9	Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13064.	1.8	14
10	Organoids as a personalized medicine tool for ultra-rare mutations in cystic fibrosis: The case of S955P and 1717-2A>G. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165905.	1.8	7
11	Protocol for Application, Standardization and Validation of the Forskolin-Induced Swelling Assay in Cystic Fibrosis Human Colon Organoids. <i>STAR Protocols</i> , 2020, 1, 100019.	0.5	69
12	Mutant CFTR Drives TWIST1 mediated epithelialâ€mesenchymal transition. <i>Cell Death and Disease</i> , 2020, 11, 920.	2.7	29
13	Assessment of Distinct Electrophysiological Parameters in Rectal Biopsies for the Choice of the Best Diagnosis/Prognosis Biomarkers for Cystic Fibrosis. <i>Frontiers in Physiology</i> , 2020, 11, 604580.	1.3	6
14	Rationale and design of the HIT-CF organoid study: stratifying cystic fibrosis patients based on intestinal organoid response to different CFTR-modulators. <i>Translational Medicine Communications</i> , 2020, 5, .	0.5	10
15	Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR. <i>Biochemical Pharmacology</i> , 2020, 180, 114133.	2.0	14
16	P204 A check of the organoid FIS assay reproducibility when performed in a newly established local lab. <i>Journal of Cystic Fibrosis</i> , 2020, 19, S114.	0.3	0
17	KLF4 Acts as a wt-CFTR Suppressor through an AKT-Mediated Pathway. <i>Cells</i> , 2020, 9, 1607.	1.8	11
18	The effect of premature termination codon mutations on <i>CFTR</i> mRNA abundance in human nasal epithelium and intestinal organoids: a basis for readâ€through therapies in cystic fibrosis. <i>Human Mutation</i> , 2019, 40, 326-334.	1.1	19

#	ARTICLE	IF	CITATIONS
19	R560S: A class II CFTR mutation that is not rescued by current modulators. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 182-189.	0.3	25
20	WS13-3 Electrophysiological measurements in rectal biopsies: a better prognosis biomarker for cystic fibrosis disease?. <i>Journal of Cystic Fibrosis</i> , 2019, 18, S24-S25.	0.3	0
21	TMEM16A chloride channel does not drive mucus production. <i>Life Science Alliance</i> , 2019, 2, e201900462.	1.3	21
22	Effect of genetic variants of OPTN in the pathophysiology of Paget's disease of bone. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 143-151.	1.8	17
23	A novel microscopy-based assay identifies extended synaptotagmin-1 (ESYT1) as a positive regulator of anoctamin 1 traffic. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2018, 1865, 421-431.	1.9	19
24	Molecular effect of an OPTN common variant associated to Paget's disease of bone. <i>PLoS ONE</i> , 2018, 13, e0197543.	1.1	10
25	Cloning, characterization and analysis of the 5' regulatory region of zebrafish xpd gene. <i>Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology</i> , 2015, 185, 47-53.	0.7	2
26	Evolutionary conservation of TFIIF subunits: Implications for the use of zebrafish as a model to study TFIIF function and regulation. <i>Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology</i> , 2014, 172-173, 9-20.	0.7	2
27	MiR-29a is an enhancer of mineral deposition in bone-derived systems. <i>Archives of Biochemistry and Biophysics</i> , 2014, 564, 173-183.	1.4	33
28	Can zebrafish be a valid model to study Paget's disease of bone?. <i>Journal of Applied Ichthyology</i> , 2014, 30, 678-688.	0.3	3
29	Molecular cloning and expression analysis of xpd from zebrafish (<i>Danio rerio</i>). <i>Molecular Biology Reports</i> , 2012, 39, 5339-5348.	1.0	8
30	Molecular characterization of two paralog genes encoding Gla-rich protein (Grp) in zebrafish. <i>Journal of Applied Ichthyology</i> , 2012, 28, 377-381.	0.3	12